MENU
BLLN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BLLN stock forecast, quote, news & analysis

BillionToOne Inc is a molecular diagnostics company... Show more

BLLN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BLLN with price predictions
Sep 18, 2026

Momentum Indicator for BLLN turns positive, indicating new upward trend

BLLN saw its Momentum Indicator move above the 0 level on September 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator turned positive. In 14 of the 15 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BLLN just turned positive on August 28, 2026. Looking at past instances where BLLN's MACD turned positive, the stock continued to rise in 7 of 8 cases over the following month. The odds of a continued upward trend are 88%.

Following a +5.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 41 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 38 of 39 cases where BLLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BLLN moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 5 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

BLLN broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.311) is normal, around the industry mean (60.700). P/E Ratio (148.207) is within average values for comparable stocks, (144.546). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.432). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 19.68B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 5%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 47%. XGN experienced the highest price growth at 20%, while ADVB experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 235%. For the same stocks of the Industry, the average monthly volume growth was 124% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 61
Price Growth Rating: 42
SMR Rating: 78
Profit Risk Rating: 90
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
BLLN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Details
Industry
N/A
Address
1035 O’Brien Drive
Phone
+1 650 460-2551
Employees
713
Web
https://www.billiontoone.com
Momentum Indicator for BLLN turns positive, indicating new upward trend